References to Hemotoxicity Testing


Literature Related to the Use of Colony-Forming Assays
  1. Boiret N, Kanold J, Fouassier M, Bons JM, Halle P, Rapatel C, Berger J, Pireyre P, Blanzat V, Travade P, Bonhomme J, Demeocq F, Berger MG: CFU-Mk content of immunoselected CD34+ peripheral blood progenitor cells, evaluated with an adapted serum-free methylcellulose assay, is predictive of platelet lineage reconstitution in children with solid tumors. J Hematother.Stem Cell Res 9: 525-534, 2000
  2. Catalano L, Selleri C, Califano C, Luciano L, Volpicelli M, Rocco S, Varriale G, Ricci P, Rotoli B: Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica 85: 133-138, 2000
  3. Drygalski A, Xu G, Constantinescu D, Kashiwakura I, Farley T, Dobrila L, Rubinstein P, Adamson JW: The frequency and proliferative potential of megakaryocytic colony-forming cells (Meg-CFC) in cord blood, cytokine-mobilized peripheral blood and bone marrow, and their correlation with total CFC numbers: implications for the quantitation of Meg-CFC to predict platelet engraftment following cord blood transplantation. Bone Marrow Transplant. 25: 1029-1034, 2000
  4. Chinnasamy N, Rafferty J, Lashford L, Chinnasamy D, Margison G, Thatcher N, Dexter T, Fairbairn L: Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cells - implications for chemoprotective gene therapy. Leukemia 13: 1776-1783, 1999
  5. D'Arena G, Musto P, Di Mauro L, Cascavilla N, Iacono ND, Scalzulli PR, Matera R, Carotenuto M: Predictive parameters for mobilized peripheral blood CD34+ progenitor cell collection in patients with hematological malignancies. Am J Hematol. 58: 255-262, 1998
  6. Feng R, Shimazaki C, Inaba T, Takahashi R, Hirai H, Kikuta T, Sumikuma T, Yamagata N, Ashihara E, Fujita N, Nakagawa M: CD34+/CD41a+ cells best predict platelet recovery after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 21: 1217-1222, 1998
  7. al Fiar F, Prince HM, Imrie K, Stewart AK, Crump M, Keating A: Bone marrow mononuclear cell count does not predict neutrophil and platelet recovery following autologous bone marrow transplant: value of the colony-forming unit granulocyte-macrophage (CFU-GM) assay. Cell Transplant. 6: 491-495, 1997
  8. Albella B, Segovia JC, Bueren JA: Does the granulocyte-macrophage colony-forming unit content in ex vivo-expanded grafts predict the recovery of the recipient leukocytes? Blood 90: 464-470, 1997
  9. Gidali J, Feher I, Harsanyi V, Reti M: Blast colony forming cells in umbilical cord blood: frequency and correlation to other haemopoietic progenitors. Haematologia (Budap.) 28: 27-32, 1996
  10. Depenbrock H, Wenger M, Peter R, Fellbaum C, Block T, Rastetter J, Hanauske AR: Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming units in vitro. Invest New Drugs 13: 117-123, 1995
  11. Straetmans N, Ma DD, Herman P, Zenebergh A, Chang A, Deneys V, De Bruyere M, Ferrant A: Long-term culture of autologous transplanted bone marrow for acute myeloid leukaemia: evidence for an in vitro haemopoietic defect and lack of correlation with the speed of engraftment. Bone Marrow Transplant. 15: 421-428, 1995
  12. Suzuki T, Muroi K, Tomizuka H, Amemiya Y, Miura Y: Characterization of enriched CD34+ cells from healthy volunteers and those from patients treated with chemotherapy plus granulocyte colony-stimulating factor (G-CSF). Stem Cells 13: 273-280, 1995
  13. Irvine AE, French A, Daly A, Ranaghan L, Morris TC: Drug-induced neutropenia due to direct effects on CFU-C--ten years of culture experience. Eur.J Haematol. 52: 21-27, 1994
  14. Tjonnfjord GE, Steen R, Evensen SA, Thorsby E, Egeland T: Characterization of CD34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood 84: 2795-2801, 1994
  15. Fernandez JM, Shepherd V, Millar J, Powles R, Pinkerton CR: When is the optimum time to harvest peripheral blood stem cells in children following standard dose chemotherapy? Med.Pediatr.Oncol. 21: 465-469, 1993
  16. Liu KY, Akashi K, Harada M, Takamatsu Y, Niho Y: Kinetics of circulating haematopoietic progenitors during chemotherapy-induced mobilization with or without granulocyte colony-stimulating factor. Br J Haematol. 84: 31-38, 1993
  17. Messner HA, Jamal N: Cell culture assessment of hematopoietic progenitors in bone marrow transplantation. J Hematother. 2: 19-25, 1993
  18. Rosenfeld CS, Nemunaitis J, Sherer CR, Zeigler ZR, Shadduck RK: c-kit ligand augments granulocyte-macrophage colony growth from patients with 5q- syndrome. Stem Cells 11: 562-567, 1993
  19. Teshima T, Harada M, Takamatsu Y, Makino K, Taniguchi S, Inaba S, Kondo S, Tanaka T, Akashi K, Minamishima I: Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant. 10: 215-220, 1992
  20. Volpe DA, Du DL, Zurlo MG, Mongelli N, Murphy MJ: Comparative in vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells. Invest New Drugs 10: 255-261, 1992
  21. Wandl UB, Niederle N, Kranzhoff M, Seeber S: Clonogenic assay is not predictive but reflects therapeutic efficacy of interferons in the treatment of chronic myelogenous leukemia. Int.J Cell Cloning 10: 292-298, 1992
  22. Fritsch G, Emminger W, Buchinger P, Printz D, Gadner H: CD34-positive cell proportions in peripheral blood correlate with colony-forming capacity. Exp.Hematol. 19: 1079-1083, 1991
  23. Rowley SD, Piantadosi S, Marcellus DC, Jones RJ, Davidson NE, Davis JM, Kennedy J, Wiley JM, Wingard JR, Yeager AM: Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts. Bone Marrow Transplant. 7: 183-191, 1991
  24. Wiley JM, Yeager AM: Predictive value of colony-forming unit assays for engraftment and leukemia-free survival after transplantation of chemopurged syngeneic bone marrow in rats. Exp.Hematol. 19: 179-184, 1991
  25. Minegishi N, Minegishi M, Tuchiya S, Konno T: Preservation of immature hematopoietic progenitor cells responding to interleukin 3 in marrow treated with 4-hydroperoxycyclophosphamide. Tohoku J Exp.Med. 159: 113-122, 1989
  26. Yung WK: In vitro chemosensitivity testing and its clinical application in human gliomas. Neurosurg.Rev. 12: 197-203, 1989
  27. Isobe Y: Pharmacodynamic study of the in vitro clonogenic assay--with reference to dose levels. Nippon Geka Gakkai Zasshi 89: 1594-1602, 1988
  28. Isobe Y, Kubota T, Asanuma F, Kurihara H, Inada T, Fukutomi T, Ishibiki K, Abe O: Pharmacodynamic aspects of in vitro and in vivo chemosensitivity tests. Jpn.J Cancer Res 78: 983-990, 1987
  29. Rowley SD, Zuehlsdorf M, Braine HG, Colvin OM, Davis J, Jones RJ, Saral R, Sensenbrenner LL, Yeager A, Santos GW: CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow. Blood 70: 271-275, 1987
  30. Slee PH, Van Oosterom AT, De Bruijn EA: Predictive testing in cancer chemotherapy. II. In vitro. Pharm.Weekbl.[Sci] 7: 125-133, 1985
  31. Weisenthal LM, Lippman ME: Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat.Rep. 69: 615-632, 1985.
Literature Related to Hemotoxicity
  1. Botta M, Castello G, Ballarino P, Arboscello E, Lerza R, Mencoboni M, Pannacciulli I: Toxicity on human hemopoietic progenitors of 2'-2'-difluoro-2'deoxycytidine (gemcitabine). Anticancer Res 18: 1037-1042, 1998
  2. Lerza R, Castello G, Ballarino P, Mela GS, Tredici S, Arboscello E, Mencoboni M, Pannacciulli I: In vitro toxicity of A 3'-azido-3'-deoxythymidine and hydroxyurea combination on normal myeloid progenitors. Anticancer Res 18: 2755-2758, 1998
  3. Holt DE, Ryder TA, Fairbairn A, Hurley R, Harvey D: The myelotoxicity of chloramphenicol: in vitro and in vivo studies: I. In vitro effects on cells in culture. Hum.Exp.Toxicol. 16: 570-576, 1997
  4. de Haan G, Engel C, Dontje B, Loeffler M, Nijhof W: Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy. Cancer Res 55: 324-329, 1995
  5. Balleari E, Massa G, Musselli C, Timitilli S, Battaglia A, Ghio R: In vivo effects of thymustimulin on hematopoiesis of mice treated with cyclophosphamide. Clin Immunol.Immunopathol. 68: 363-367, 1993
  6. Esposito M, Lerza R, Mencoboni M, Vannozzi M, Flego G, Bogliolo G, Merlo F, Pannacciulli I: Protective effect on cisplatin hematotoxicity by procaine hydrochloride. Cancer Lett. 64: 55-60, 1992
  7. Bogliolo G, Lerza R, Mencoboni M, Flego G, Gasparini L, Pannacciulli I: Hemotoxic effects on mice of combined administration of azidothymidine and acyclovir. Exp.Hematol. 19: 838-841, 1991
  8. Juraskova V, Brabec V: Evaluation of cytotoxic and antitumor effects of a tetravalent analog of carboplatin. Neoplasma 36: 297-303, 1989
  9. Lerza R, Bogliolo G, Mencoboni M, Saviane A, Pannacciulli I: Studies on hemotoxicity of cyclophosphamide, doxorubicin and cis-diamminodichloroplatinum combined with sodium-2-mercaptoethane sulfonate. Tumori 74: 333-337, 1988
  10. Lerza RA, Bogliolo GV, Mencoboni MP, Saviane AG, Pannacciulli IM: Effect of H2 antagonists cimetidine and famotidine on the hemotoxicity of cyclophosphamide. Anticancer Res 8: 1241-1245, 1988
  11. Gaido K, Wierda D: In vitro effects of benzene metabolites on mouse bone marrow stromal cells. Toxicol.Appl.Pharmacol 76: 45-55, 1984
  12. Bogliolo G, Ronco D, Massa G, Dolcino G, Mansi C, Pannacciulli I: Effects of erythropoietic activation on the hemotoxicity of cyclophosphamide. Arch.Maragliano.Patol.Clin 29: 153-157, 1973
  13. Dolcino G, Ronco D, Massa G, Bogliolo G, Testa R, Pannacciulli I: Effects of bleeding on experimental hemotoxicity of chlorambucil. Arch.Maragliano.Patol.Clin 29: 149-152, 1973